Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 28, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 1,300,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,307 pence per share; lowest price paid was 1,291.5 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.85% of total issued share capital and 9.71% of total voting rights).
- Shares in Issue: 5,138,237,085 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 1,300,000 repurchased shares. Consequently, the Company's Treasury shareholding increased to 499,174,284 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,138,237,085) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share percentage (8.85% of issued capital) for voting rights analysis.
- Review the remaining authorization for share buybacks following this transaction.